ADMA BIOLOGICS INC (ADMA) Fundamental Analysis & Valuation

NASDAQ:ADMA • US0008991046

15.39 USD
-0.31 (-1.97%)
At close: Mar 6, 2026
15.41 USD
+0.02 (+0.13%)
After Hours: 3/6/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ADMA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Overall ADMA gets a fundamental rating of 6 out of 10. We evaluated ADMA against 520 industry peers in the Biotechnology industry. ADMA has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. ADMA may be a bit undervalued, certainly considering the very reasonable score on growth This makes ADMA very considerable for value and quality investing!


Dividend Valuation Growth Profitability Health

7

1. ADMA Profitability Analysis

1.1 Basic Checks

  • In the past year ADMA was profitable.
  • ADMA had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: ADMA reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
ADMA Yearly Net Income VS EBIT VS OCF VS FCFADMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • ADMA has a better Return On Assets (23.54%) than 97.12% of its industry peers.
  • The Return On Equity of ADMA (30.78%) is better than 96.92% of its industry peers.
  • The Return On Invested Capital of ADMA (27.76%) is better than 98.65% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for ADMA is in line with the industry average of 19.05%.
  • The 3 year average ROIC (20.20%) for ADMA is below the current ROIC(27.76%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 23.54%
ROE 30.78%
ROIC 27.76%
ROA(3y)18.47%
ROA(5y)2.12%
ROE(3y)22.18%
ROE(5y)-5.51%
ROIC(3y)20.2%
ROIC(5y)N/A
ADMA Yearly ROA, ROE, ROICADMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • The Profit Margin of ADMA (28.80%) is better than 95.00% of its industry peers.
  • ADMA has a Operating Margin of 37.52%. This is amongst the best in the industry. ADMA outperforms 97.12% of its industry peers.
  • ADMA has a Gross Margin of 57.39%. This is in the better half of the industry: ADMA outperforms 77.69% of its industry peers.
  • In the last couple of years the Gross Margin of ADMA has grown nicely.
Industry RankSector Rank
OM 37.52%
PM (TTM) 28.8%
GM 57.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y35.81%
GM growth 5YN/A
ADMA Yearly Profit, Operating, Gross MarginsADMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ADMA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ADMA is creating value.
  • ADMA has more shares outstanding than it did 1 year ago.
  • ADMA has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, ADMA has an improved debt to assets ratio.
ADMA Yearly Shares OutstandingADMA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ADMA Yearly Total Debt VS Total AssetsADMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • ADMA has an Altman-Z score of 17.50. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
  • ADMA's Altman-Z score of 17.50 is amongst the best of the industry. ADMA outperforms 88.27% of its industry peers.
  • ADMA has a debt to FCF ratio of 2.62. This is a good value and a sign of high solvency as ADMA would need 2.62 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 2.62, ADMA belongs to the top of the industry, outperforming 93.08% of the companies in the same industry.
  • ADMA has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
  • ADMA has a Debt to Equity ratio of 0.15. This is in the lower half of the industry: ADMA underperforms 63.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.62
Altman-Z 17.5
ROIC/WACC3.15
WACC8.82%
ADMA Yearly LT Debt VS Equity VS FCFADMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 6.71 indicates that ADMA has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 6.71, ADMA is in the better half of the industry, outperforming 68.27% of the companies in the same industry.
  • ADMA has a Quick Ratio of 3.74. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.74, ADMA perfoms like the industry average, outperforming 47.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.71
Quick Ratio 3.74
ADMA Yearly Current Assets VS Current LiabilitesADMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ADMA Growth Analysis

3.1 Past

  • ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.00%, which is quite good.
  • Looking at the last year, ADMA shows a quite strong growth in Revenue. The Revenue has grown by 19.63% in the last year.
  • The Revenue has been growing by 64.62% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)19.63%
Revenue growth 3Y49.04%
Revenue growth 5Y64.62%
Sales Q2Q%18.39%

3.2 Future

  • ADMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.23% yearly.
  • Based on estimates for the next years, ADMA will show a quite strong growth in Revenue. The Revenue will grow by 19.85% on average per year.
EPS Next Y53.85%
EPS Next 2Y41.43%
EPS Next 3Y38.57%
EPS Next 5Y35.23%
Revenue Next Year24.85%
Revenue Next 2Y22.97%
Revenue Next 3Y22.47%
Revenue Next 5Y19.85%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADMA Yearly Revenue VS EstimatesADMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
ADMA Yearly EPS VS EstimatesADMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

8

4. ADMA Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 25.65, the valuation of ADMA can be described as expensive.
  • 92.69% of the companies in the same industry are more expensive than ADMA, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of ADMA to the average of the S&P500 Index (26.29), we can say ADMA is valued inline with the index average.
  • The Price/Forward Earnings ratio is 16.67, which indicates a correct valuation of ADMA.
  • Based on the Price/Forward Earnings ratio, ADMA is valued cheaper than 94.42% of the companies in the same industry.
  • ADMA's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.57.
Industry RankSector Rank
PE 25.65
Fwd PE 16.67
ADMA Price Earnings VS Forward Price EarningsADMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ADMA is valued cheaply inside the industry as 93.65% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, ADMA is valued cheaper than 91.15% of the companies in the same industry.
Industry RankSector Rank
P/FCF 133.26
EV/EBITDA 18.66
ADMA Per share dataADMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ADMA has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as ADMA's earnings are expected to grow with 38.57% in the coming years.
PEG (NY)0.48
PEG (5Y)N/A
EPS Next 2Y41.43%
EPS Next 3Y38.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ADMA Dividend Analysis

5.1 Amount

  • ADMA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADMA Fundamentals: All Metrics, Ratios and Statistics

ADMA BIOLOGICS INC

NASDAQ:ADMA (3/6/2026, 8:00:00 PM)

After market: 15.41 +0.02 (+0.13%)

15.39

-0.31 (-1.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners93.5%
Inst Owner Change-2.89%
Ins Owners2.35%
Ins Owner Change3.92%
Market Cap3.67B
Revenue(TTM)510.17M
Net Income(TTM)146.93M
Analysts82.22
Price Target26.18 (70.11%)
Short Float %9.25%
Short Ratio8.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.01%
Min EPS beat(2)-1.96%
Max EPS beat(2)5.99%
EPS beat(4)1
Avg EPS beat(4)-7.27%
Min EPS beat(4)-31.17%
Max EPS beat(4)5.99%
EPS beat(8)4
Avg EPS beat(8)9.68%
EPS beat(12)6
Avg EPS beat(12)-7.7%
EPS beat(16)8
Avg EPS beat(16)-5.55%
Revenue beat(2)1
Avg Revenue beat(2)-0.66%
Min Revenue beat(2)-2.13%
Max Revenue beat(2)0.81%
Revenue beat(4)1
Avg Revenue beat(4)-1.78%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)0.81%
Revenue beat(8)5
Avg Revenue beat(8)3.94%
Revenue beat(12)9
Avg Revenue beat(12)4.07%
Revenue beat(16)13
Avg Revenue beat(16)4.88%
PT rev (1m)0%
PT rev (3m)-5.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.87%
Valuation
Industry RankSector Rank
PE 25.65
Fwd PE 16.67
P/S 7.18
P/FCF 133.26
P/OCF 72.73
P/B 7.68
P/tB 7.75
EV/EBITDA 18.66
EPS(TTM)0.6
EY3.9%
EPS(NY)0.92
Fwd EY6%
FCF(TTM)0.12
FCFY0.75%
OCF(TTM)0.21
OCFY1.37%
SpS2.14
BVpS2
TBVpS1.99
PEG (NY)0.48
PEG (5Y)N/A
Graham Number5.2
Profitability
Industry RankSector Rank
ROA 23.54%
ROE 30.78%
ROCE 34.51%
ROIC 27.76%
ROICexc 32.97%
ROICexgc 33.27%
OM 37.52%
PM (TTM) 28.8%
GM 57.39%
FCFM 5.39%
ROA(3y)18.47%
ROA(5y)2.12%
ROE(3y)22.18%
ROE(5y)-5.51%
ROIC(3y)20.2%
ROIC(5y)N/A
ROICexc(3y)25.15%
ROICexc(5y)N/A
ROICexgc(3y)25.44%
ROICexgc(5y)N/A
ROCE(3y)25.11%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y35.81%
GM growth 5YN/A
F-Score6
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.62
Debt/EBITDA 0.35
Cap/Depr 282.75%
Cap/Sales 4.49%
Interest Coverage 21.09
Cash Conversion 25.26%
Profit Quality 18.72%
Current Ratio 6.71
Quick Ratio 3.74
Altman-Z 17.5
F-Score6
WACC8.82%
ROIC/WACC3.15
Cap/Depr(3y)149.71%
Cap/Depr(5y)178.08%
Cap/Sales(3y)2.81%
Cap/Sales(5y)6.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y53.85%
EPS Next 2Y41.43%
EPS Next 3Y38.57%
EPS Next 5Y35.23%
Revenue 1Y (TTM)19.63%
Revenue growth 3Y49.04%
Revenue growth 5Y64.62%
Sales Q2Q%18.39%
Revenue Next Year24.85%
Revenue Next 2Y22.97%
Revenue Next 3Y22.47%
Revenue Next 5Y19.85%
EBIT growth 1Y37.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.74%
EBIT Next 3Y42.39%
EBIT Next 5Y35.13%
FCF growth 1Y-75.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.53%
OCF growth 3YN/A
OCF growth 5YN/A

ADMA BIOLOGICS INC / ADMA FAQ

What is the fundamental rating for ADMA stock?

ChartMill assigns a fundamental rating of 6 / 10 to ADMA.


What is the valuation status of ADMA BIOLOGICS INC (ADMA) stock?

ChartMill assigns a valuation rating of 8 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Undervalued.


How profitable is ADMA BIOLOGICS INC (ADMA) stock?

ADMA BIOLOGICS INC (ADMA) has a profitability rating of 7 / 10.


What is the financial health of ADMA BIOLOGICS INC (ADMA) stock?

The financial health rating of ADMA BIOLOGICS INC (ADMA) is 7 / 10.